• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by BioAtla Inc. (Amendment)

    2/6/24 3:57:34 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BCAB alert in real time by email
    SC 13G/A 1 p24-0352sc13ga.htm BIOATLA, INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
     

    BioAtla, Inc.

    (Name of Issuer)
     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)
     

    09077B104

    (CUSIP Number)
     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    x Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 10 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 09077B10413G/APage 2 of 10 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Acorn Bioventures, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ☒

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    1,824,918

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    1,824,918

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,824,918

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.8%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     

     

    CUSIP No. 09077B10413G/APage 3 of 10 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Acorn Capital Advisors GP, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ☒

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    1,824,918

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    1,824,918

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,824,918

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.8%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

     

    CUSIP No. 09077B10413G/APage 4 of 10 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Acorn Bioventures 2 L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ☒

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    2,207,128

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    2,207,128

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,207,128

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.6%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

    CUSIP No. 09077B10413G/APage 5 of 10 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Acorn Capital Advisors GP 2, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ☒

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    2,207,128

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    2,207,128

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,207,128

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.6%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

    CUSIP No. 09077B10413G/APage 6 of 10 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Anders Hove

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ☒

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States of America

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    4,032,046

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    4,032,046

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,032,046

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.4%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

    CUSIP No. 09077B10413G/APage 7 of 10 Pages

     

    Item 1(a). Name of Issuer:
       
      BioAtla, Inc. (the "Issuer")

     

    Item 1(b). Address of Issuer's Principal Executive Offices:
       
     

    11085 Torreyana Road

    San Diego, California 92121

     

    Item 2(a). Name of Person Filing:
       
      This statement is filed by:
       
      (i) Acorn Bioventures, L.P. (“Acorn”);
      (ii) Acorn Capital Advisors GP, LLC (“Acorn GP”), which is the sole general partner of Acorn;
      (iii) Acorn Bioventures 2, L.P. (“Acorn 2”);
      (iv) Acorn Capital Advisors GP 2, LLC (“Acorn GP 2”), which is the sole general partner of Acorn 2; and
      (v) Anders Hove (“Hove or “Manager”).
         
      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."  
       
      The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.  
       
    Item 2(b). Address of Principal Business Office:
       
      The address of the principal business office of each of the Reporting Persons is 420 Lexington Avenue, Suite 2626, New York, New York 10170
       
    Item 2(c). Place of Organization:
       
      Acorn is a Delaware limited partnership. Acorn GP is a Delaware limited liability company. Acorn 2 is a Delaware limited partnership. Acorn GP 2 is a Delaware limited liability company. Each of Hove and Manke are citizens of the United States of America.

     

    Item 2(d). Title of Class of Securities:
       
      Common stock, $0.0001 par value per share (the "Common Stock")

     

    Item 2(e). CUSIP Number:
       
      09077B104

     

     

    CUSIP No. 09077B10413G/APage 8 of 10 Pages

     

    Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:

     

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) ¨ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

      (g) o

    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K).
     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:                                                                                     

     

    Item 4. Ownership:
       
      The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.  
       
      The percentages set forth herein are calculated based upon 47,935,808 shares of Common Stock outstanding as of November 6, 2023 as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 filed with the Securities and Exchange Commission on November 13, 2023.
       

     

    CUSIP No. 09077B10413G/APage 9 of 10 Pages

     

      Acorn GP is the general partner of Acorn and may be deemed to beneficially own the shares of Common Stock beneficially owned by Acorn.  Acorn GP 2 is the general partner of Acorn 2 and may be deemed to beneficially own the shares of Common Stock beneficially owned by Acorn 2.
       
      The Manager, in his capacity as manager of each of Acorn GP and Acorn GP 2, may be deemed to beneficially own the shares beneficially owned by each of Acorn and Acorn 2.

     

    Item 5. Ownership of Five Percent or Less of a Class:
       
      Not applicable.

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person:
       
      Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:
       
      Not applicable.

     

    Item 8. Identification and Classification of Members of the Group:
       
      Not applicable.

     

    Item 9. Notice of Dissolution of Group:
       
      Not applicable.

     

    Item 10. Certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

    CUSIP No. 09077B10413G/APage 10 of 10 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date:  February 6, 2024  
      ACORN BIOVENTURES, L.P.
      By: ACORN CAPITAL ADVISORS GP, LLC, its General Partner
      By:  /s/ Anders Hove
      Name:  Anders Hove   
      Title:    Manager
       
       
      ACORN CAPITAL ADVISORS GP, LLC
      By:  /s/ Anders Hove
      Name:  Anders Hove   
      Title:    Manager
       
       
      ACORN BIOVENTURES 2, L.P.
      By: ACORN CAPITAL ADVISORS GP 2, LLC, its General Partner
      By:  /s/ Anders Hove
      Name:  Anders Hove   
      Title:    Manager
       
       
      ACORN CAPITAL ADVISORS GP 2, LLC
      By:  /s/ Anders Hove
      Name:  Anders Hove   
      Title:    Manager
       
       
      ANDERS HOVE
      /s/ Anders Hove
       

     

    Get the next $BCAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BCAB

    DatePrice TargetRatingAnalyst
    11/13/2024Buy → Neutral
    H.C. Wainwright
    9/15/2022$17.00Mkt Outperform
    JMP Securities
    5/5/2022$35.00 → $5.00Outperform → Neutral
    Credit Suisse
    3/21/2022$25.00Buy
    H.C. Wainwright
    10/15/2021$68.00Buy
    BTIG Research
    6/28/2021$75.00Buy
    ROTH Capital
    More analyst ratings

    $BCAB
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by BioAtla Inc.

      SCHEDULE 13G/A - BioAtla, Inc. (0001826892) (Subject)

      5/20/25 2:26:28 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioAtla Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - BioAtla, Inc. (0001826892) (Filer)

      5/16/25 5:05:56 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B3 filed by BioAtla Inc.

      424B3 - BioAtla, Inc. (0001826892) (Filer)

      5/16/25 4:22:32 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Vasquez Christian was granted 85,000 shares, increasing direct ownership by 44% to 276,696 units (SEC Form 4)

      4 - BioAtla, Inc. (0001826892) (Issuer)

      3/13/25 4:12:55 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Short Jay M Phd was granted 431,000 shares, increasing direct ownership by 24% to 2,256,372 units (SEC Form 4)

      4 - BioAtla, Inc. (0001826892) (Issuer)

      3/13/25 4:12:28 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Waldron Richard A was granted 100,000 shares, increasing direct ownership by 43% to 333,263 units (SEC Form 4)

      4 - BioAtla, Inc. (0001826892) (Issuer)

      3/13/25 4:12:02 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCAB
    Leadership Updates

    Live Leadership Updates

    See more
    • BIOATLA APPOINTS EDWARD L. WILLIAMS TO BOARD OF DIRECTORS

      SAN DIEGO, Dec. 21, 2021 /PRNewswire/ -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that Edward L. (Eddie) Williams has been appointed to the BioAtla Board of Directors and has agreed to serve on the Audit Committee of the Board.  Mr. Williams has extensive executive experience in the biopharmaceutical industry and as a member of the board of directors of a biotechnology company in late-stage clinical development. Jay M. Short, Ph.D., Chairman of the Board and Chief Executive Officer, stated, "Eddie's career of demonstrated success and knowledge in growing biopharmaceuti

      12/21/21 9:00:00 AM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mcbrinn Sylvia bought $9,400 worth of shares (4,000 units at $2.35), increasing direct ownership by 26% to 19,125 units (SEC Form 4)

      4 - BioAtla, Inc. (0001826892) (Issuer)

      1/19/24 4:21:50 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mcbrinn Sylvia bought $9,320 worth of shares (4,000 units at $2.33), increasing direct ownership by 36% to 15,125 units (SEC Form 4)

      4 - BioAtla, Inc. (0001826892) (Issuer)

      12/26/23 7:43:02 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Short Jay M Phd bought $106,910 worth of shares (50,000 units at $2.14), increasing direct ownership by 4% to 1,439,283 units (SEC Form 4)

      4 - BioAtla, Inc. (0001826892) (Issuer)

      12/20/23 6:27:44 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress

      CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study ongoing, dosed first three patients at 300 micrograms; data readout expected mid-2025 with dose expansion data readout anticipated 1H 2026Mecbotamab vedotin (Mec-V; CAB-AXL-ADC) continues to demonstrate exceptional overall survival (OS) with a 2-year landmark survival of 59% in mKRAS non-small cell lung cancer (NSCLC); Previous studies have reported 2-year landmark survival less than 20% among patients treated with standard of care agentsOzuriftamab vedotin (Oz-V; CAB-ROR2-ADC) Phase 2 study continues to demonstrate compelling signals in HPV-positive squamous cell carcinoma of the head and neck (SCCHN) patients; Company utilizing Fas

      5/6/25 4:05:00 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioAtla to Participate in the Citizens Life Sciences Conference

      SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company's management will provide a corporate update and participate in one-on-one investor meetings at the Citizens Life Sciences Conference, to be held in New York, NY May 7-8, 2025. Format: Corporate update and one-on-one investor meetingsDate: Wednesday, May 7, 2025Time: 10:00 a.m. ETLocation: New York, NYWebcast Link: Click Here About BioAtla®, Inc.BioAtla is a global clinical-stage biotechnology company with operation

      4/30/25 8:00:00 AM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025

      SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, May 6, 2025 at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2025 and provide business highlights. Conference Call and Webcast Information        Date: Tuesday, May 6, 2025Time: 4:30 p.m. ETWebcast Link: BioAtla First Quarter 2025 Earnings Conference Call Dial-in Numbers: (800) 245-3047 (domestic), (203) 518-9765 (international)Con

      4/29/25 8:00:00 AM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by BioAtla Inc.

      SC 13G/A - BioAtla, Inc. (0001826892) (Subject)

      11/14/24 4:00:05 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BioAtla Inc.

      SC 13D/A - BioAtla, Inc. (0001826892) (Subject)

      10/2/24 4:30:04 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BioAtla Inc.

      SC 13D/A - BioAtla, Inc. (0001826892) (Subject)

      9/6/24 4:59:38 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCAB
    Financials

    Live finance-specific insights

    See more
    • BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress

      CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study ongoing, dosed first three patients at 300 micrograms; data readout expected mid-2025 with dose expansion data readout anticipated 1H 2026Mecbotamab vedotin (Mec-V; CAB-AXL-ADC) continues to demonstrate exceptional overall survival (OS) with a 2-year landmark survival of 59% in mKRAS non-small cell lung cancer (NSCLC); Previous studies have reported 2-year landmark survival less than 20% among patients treated with standard of care agentsOzuriftamab vedotin (Oz-V; CAB-ROR2-ADC) Phase 2 study continues to demonstrate compelling signals in HPV-positive squamous cell carcinoma of the head and neck (SCCHN) patients; Company utilizing Fas

      5/6/25 4:05:00 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025

      SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, May 6, 2025 at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2025 and provide business highlights. Conference Call and Webcast Information        Date: Tuesday, May 6, 2025Time: 4:30 p.m. ETWebcast Link: BioAtla First Quarter 2025 Earnings Conference Call Dial-in Numbers: (800) 245-3047 (domestic), (203) 518-9765 (international)Con

      4/29/25 8:00:00 AM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

      CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated 1H 2026 Mecbotamab vedotin (CAB-AXL-ADC) Q2W dosing regimen associated with exceptional overall survival (OS) with 66% and 58% of patients with mKRAS NSCLC alive at a landmark one-year and two-years, respectively, which exceeds the reported standard of care Ozuriftamab vedotin (CAB-ROR2-ADC) demonstrated compelling anti-tumor activity in treatment-refractory, metastatic HPV-positive squamous cell carcinoma of the head and neck (SCCHN); a population which is poorly served by EGFR inhibitorsCash balance of $49mm at year-end 2024 with recent cost-redu

      3/27/25 4:05:00 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BioAtla downgraded by H.C. Wainwright

      H.C. Wainwright downgraded BioAtla from Buy to Neutral

      11/13/24 7:31:56 AM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JMP Securities initiated coverage on BioAtla with a new price target

      JMP Securities initiated coverage of BioAtla with a rating of Mkt Outperform and set a new price target of $17.00

      9/15/22 7:31:28 AM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioAtla downgraded by Credit Suisse with a new price target

      Credit Suisse downgraded BioAtla from Outperform to Neutral and set a new price target of $5.00 from $35.00 previously

      5/5/22 6:12:47 AM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care